Cytora Stem

CYTORA is a clinical stage stem cell company developing a new class of medicines based on a novel and transformative patented platform stem cell technology derived from unique human Oral Mucosa Stem Cells (hOMSC) CYTORA has developed a revolutionary patent protected technology platform to produce “off the shelf” (allogeneic) therapeutic doses of hOMSC to treat some of the most challenging diseases of this decade including chronic wounds such as incurable diabetic foot ulcers (IDFU) and degenerative diseases such as Parkinson's Disease, Multiple System Atrophy (MSA), and Alzheimer’s Disease. Our pioneering and deeply scientific team are leading the way in stem cell therapy have years of research, patents and industry experience in the fields of biotechnology and stem cell therapy. Our vision is to improve and save the lives of millions of patients worldwide through our unique patented stem cell platform technology, making it accessible and affordable.